BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haddadin M, Al-Sadawi M, Madanat S, Tam E, Taiwo E, Luhrs C, Mcfarlane SI. Late Presentation of Carfilzomib Associated Thrombotic Microangiopathy. Am J Med Case Rep 2019;7:240-3. [PMID: 31457071 DOI: 10.12691/ajmcr-7-10-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Blasco M, Martínez-Roca A, Rodríguez-Lobato LG, Garcia-Herrera A, Rosiñol L, Castro P, Fernández S, Quintana LF, Cibeira MT, Bladé J, Fernández de Larrea C, Tovar N, Jimenez R, Poch E, Guillen E, Campistol JM, Carreras E, Diaz-Ricart M, Palomo M. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. Br J Haematol 2021;193:181-7. [PMID: 32469083 DOI: 10.1111/bjh.16796] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
2 Jindal N, Jandial A, Jain A, Lad D, Prakash G, Khadwal A, Nada R, Sethi J, Ahluwalia J, Malhotra P. Carfilzomib-induced thrombotic microangiopathy: A case based review. Hematol Oncol Stem Cell Ther 2020:S1658-3876(20)30118-7. [PMID: 32735793 DOI: 10.1016/j.hemonc.2020.07.001] [Reference Citation Analysis]
3 Jeyaraman P, Borah P, Singh A, Chhabra GD, Khullar D, Dayal N, Naithani R. Thrombotic microangiopathy after carfilzomib in a very young myeloma patient. Blood Cells Mol Dis 2020;81:102400. [PMID: 31887694 DOI: 10.1016/j.bcmd.2019.102400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
4 Rassner M, Jung J, Schneider J, Wäsch R, Engelhardt M. Dapsone-Induced Hemolytic Anemia in Multiple Myeloma: Case Report of Various Differential Diagnoses. Clin Lymphoma Myeloma Leuk 2020;20:e821-5. [PMID: 32753123 DOI: 10.1016/j.clml.2020.06.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Rassner M, Baur R, Wäsch R, Schiffer M, Schneider J, Mackensen A, Engelhardt M. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. BMC Nephrol 2021;22:32. [PMID: 33461512 DOI: 10.1186/s12882-020-02226-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Camilleri M, Cuadrado M, Phillips E, Wilson W, Jenner R, Pang G, Kamora S, Streetly M, Popat R, Bygrave C, Owen R, Cavenagh J, Chapman M, Sive J, Eccersley L, Sheaff M, Benjamin R, Ramasamy K, Cook G, Virchis A, Chavda SJ, Clifton-Hadley L, Scully MA, Yong K. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. Br J Haematol 2021;193:750-60. [PMID: 33650100 DOI: 10.1111/bjh.17377] [Reference Citation Analysis]
7 Darwin A, Malpica L, Dhanoa J, Hashmi H. Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success. BMJ Case Rep 2021;14:e239091. [PMID: 33637496 DOI: 10.1136/bcr-2020-239091] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]